Editas Medicine

Editas Medicine is hoping for a reversal of fortunes, having recently abandoned its lead candidate and laid off three quarters of its workforce after failing to find a partner for the asset, reni-c

The end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capit

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. MacroGenics Gets $40m Up Front For St

The tally of biopharmaceutical companies that have gone public in the US in 2024 has now surpassed not only last year’s total but the total from 2022 now that Septerna Inc. has launched its IPO, gross